Sanofi and Regeneron Expanded Immunology Collaboration
The pharmaceutical firms have launched a new joint program focused on four antibodies following a patent litigation settlement.
Updated on Oct. 14, 2026 in Biotech
Live Poll
Do you believe large pharmaceutical companies collaborating on drug development is generally good for the public?
Sanofi and Regeneron have entered into a new collaboration agreement to develop four antibodies targeting IL-13, IL-4, and IL-4Rα. This expansion includes a $1 billion upfront payment from Sanofi to Regeneron as part of an $8 billion deal structure.
Why it matters
The deal signals a renewed alignment between the companies, combining Regeneron's research-heavy approach with Sanofi's global commercial infrastructure. The partnership builds upon their existing profit-sharing model for the successful immunology drug Dupixent.
The agreement includes a phase 1 program for REGN20423, an antibody targeting atopic dermatitis. The partners will split costs and profits equally for the four new programs, which focus on the IL-4 and IL-13 signaling pathways.
The players
Sanofi
A global pharmaceutical company focused on immunology, vaccines, and oncology therapies.
Regeneron
A biotechnology firm specializing in large-scale human genetics and antibody discovery platforms.
The details
Regeneron will manage research and development for the new candidates, while Sanofi will handle global commercialization. The collaboration targets four antibodies, including a bispecific antibody—a single molecule engineered to bind to two distinct antigens—specifically for IL-4 and IL-13. The companies are also evaluating the inclusion of lunsekimig, an experimental drug, contingent on the conclusion of its current phase 3 studies.
Timeline
October 1, 2026: The companies announced the expansion of their immunology collaboration.
2027: Three of the new antibodies are projected to initiate clinical studies.
The Tech Race
The deal reinforces the partners' position in the competitive immunology space by pooling resources for a new pipeline. This strategic alignment mimics the development path of their prior joint success while formalizing a long-term research commitment.
Patients may eventually see new therapies for atopic dermatitis and related immunological conditions as the programs move through clinical trials. The partnership structure suggests that future market availability will rely on the dual-company infrastructure already established for existing treatments.
The takeaway
The expansion signals a deepening integration of R&D and commercial resources between these two pharmaceutical entities. Watch for the initiation of clinical studies for the three primary antibodies in 2027 as a key milestone for the pipeline's technical viability.
What happens next
Regeneron holds an option to incorporate lunsekimig into the collaboration framework following the successful completion of the drug's ongoing phase 3 clinical trials.
Further reading
Explore the latest developments in the Biotech sector to see how these antibody programs align with broader industry trends.
Source note: This article includes information reported by Big Molecule Watch.
Live Poll
Do you believe large pharmaceutical companies collaborating on drug development is generally good for the public?
